Day: December 18, 2024

Reykjavík Energy (Orkuveita Reykjavíkur) has published an addendum to the base prospectus dated 2 October 2024.The purpose of the addendum is to update the company’s green financing framework to align it with the European Union taxonomy. This alignment has been independently verified by S&P Global and the addendum has now been approved by the Central Bank of Iceland’s Financial Supervision. The addendum is attached herewith (in Icelandic) and will also be published on the issuer’s website, www.or.is. The base prospectus and the addendum will be available on the website during the validity period of the base prospectus and at the issuer’s office at Bæjarháls 1, Reykjavík. Fossar Investment Bank hf. managed the process of having the addendum to the base prospectus approved by the Central Bank of Iceland’s...

Clinical Data from First Subject Dosed Twice Daily with QRX003 in Open Label Study Is Positive at Mid-point of Testing Significant Improvement in Skin Appearance Observed in Pediatric Study after Only 12 Days of Dosing with QRX003ASHBURN, Va., Dec. 18, 2024 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive interim clinical data from two of its ongoing Netherton Syndrome clinical studies. Data from the first subject being dosed twice-daily in Quoin’s ongoing open label study is suggestive of clinical efficacy across a number of measured endpoints after six weeks of dosing with QRX003, which is the midpoint of testing. At baseline, prior to dosing, the subject’s Modified Ichthyosis...

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025. ASPEN-06 is a randomized, multi-center, international trial (NCT05002127) evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab,...

TORONTO, Dec. 18, 2024 (GLOBE NEWSWIRE) — CHAR Technologies (“CHAR Tech” or the “Company”) (TSXV:YES), a leader in sustainable energy solutions, is pleased to announce that the Government of Québec, through the Programme Innovation Bois, has announced the approval of $2.5M to CHAR Tech to support the advancement of the previously announced build, own, operate project to convert wood wastes and residuals into both biocarbon for metallurgical coal replacement, as well as green hydrogen, which the project intends to upgrade further into renewable natural gas. The non-repayable grant funding will be disbursed on predetermined project milestones. Also announced was a $1M contribution from the Programme Innovation Bois to la Société de cogénération de Saint-Félicien (“SCSF”) towards the centre de valorisation de la biomasse (“CVB”),...

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. A live webcast will be available in the Investors & Media section of the company’s website at www.septerna.com and will be archived for 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led...

ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies.– Inflammasome ASC Inhibitor IC 100 designed to attenuate initiation and perpetuation of disease-causing inflammation; lead indication: obesity with metabolic complications (e.g., cardiovascular disease). – Cholesterol Efflux Mediator™ VAR 200 designed to mediate removal of renal lipids and cholesterol that lead to kidney damage and disease; phase 2a clinical trial in diabetic kidney disease expected to begin Q1-2025.Mr. Glover welcomes one-on-one meetings to discuss ZyVersa’s technology, pipeline assets, and key development milestones.WESTON, Fla., Dec. 18, 2024 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing...

– $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Million Convertible Debt – – New Facility Represents $150 Million Strategic Investment Led by Healthcare Specialist Athyrium Capital Management and Joined by HealthCare Royalty – ANN ARBOR, Mich., Dec. 18, 2024 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has closed on a series of financing transactions that will support the Company’s repayment of a portion of its existing $265 million convertible debt facility. The transactions included a $150 million senior secured term loan facility (the “Loan”) led by funds managed by Athyrium Capital Management, LP (“Athyrium”) and joined by funds managed by HealthCare Royalty (“HCRx”), and issuance of new $100 million Convertible...